Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Feb 28:12:827395.
doi: 10.3389/fcimb.2022.827395. eCollection 2022.

Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials

Jie Wu  1 , Liang Lv  1 , Chunlian Wang  1
Affiliations
Meta-Analysis

Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials

Jie Wu et al. Front Cell Infect Microbiol. .

Abstract

Background: Randomized controlled trials (RCTs) have examined the efficacy of fecal microbiota transplantation (FMT) in irritable bowel syndrome (IBS) with inconsistent results. We performed a meta-analysis to assess both the short- and long-term efficacy of FMT in IBS.

Methods: MEDLINE, EMBASE, and the Cochrane Central Register were searched through September 2021. RCTs recruiting adult patients with IBS that compared FMT with placebo with dichotomous data of response to therapy were eligible. Dichotomous data were pooled to obtain a relative risk (RR) of symptom not improving after therapy. RR was also pooled for adverse events (AEs). Continuous data were calculated using a mean difference for IBS-Quality of Life (IBS-QoL). GRADE methodology was used to assess quality of evidence.

Results: The search strategy generated 658 citations. Seven RCTs comprising 472 patients with IBS were included. FMT was not associated with a significant improvement in global symptom in IBS at 12 weeks in comparison with placebo (RR 0.75, 95% CI 0.43-1.31) with high heterogeneity between studies (I2 87%). Subgroup analyses showed that FMT was superior to placebo when administered via colonoscopy or gastroscope (RR 0.70, 95% CI 0.51-0.96; RR 0.37, 95% CI 0.14-0.99, respectively, while FMT was inferior to placebo when administered via oral capsules (RR 1.88, 95% CI 1.06-3.35). FMT induced a significant improvement in IBS-QoL compared to placebo (mean difference 9.39, 95% CI 3.86-14.91) at 12 weeks. No significant difference in the total number of AEs was observed between FMT and placebo (RR 1.20, 95% CI 0.59-2.47). FMT did not significantly improve global symptom in IBS at 1-year follow-up compared with placebo (RR 0.90, 95% CI 0.72-1.12). The GRADE quality evidence to support recommending FMT in IBS was very low.

Conclusion: IBS patients may benefit from FMT when administered via colonoscopy or gastroscope. FMT may improve the quality of life of IBS. The long-term use of FMT in IBS warrants further investigation. There is very-low-quality evidence to support recommending FMT in IBS.

Keywords: fecal microbiota transplantation; intestinal microbiota; irritable bowel syndrome; meta-analysis; microbiota.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of included RCTs identified for meta-analysis.
Figure 2
Figure 2
Forest plot of all included RCTs of global symptom not improving in comparison between FMT and placebo in irritable bowel syndrome at 12 weeks.
Figure 3
Figure 3
Forest plot of RCTs of quality of life in comparison between FMT and placebo in irritable bowel syndrome.
Figure 4
Figure 4
Forest plot of RCTs of adverse events in comparison between FMT and placebo in irritable bowel syndrome.
Figure 5
Figure 5
Forest plot of all included RCTs of global symptom not improving in comparison between FMT and placebo in irritable bowel syndrome at the 1-year follow-up.
Figure 6
Figure 6
Risk-of-bias assessment of randomized controlled trials using Cochrane risk of bias tool.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Allegretti J. R., Kassam Z., Mullish B. H., Chiang A., Carrellas M., Hurtado J., et al. . (2020). Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clin. Gastroenterol. Hepatol. 18 (4), 855–863 e852. doi: 10.1016/j.cgh.2019.07.006 - DOI - PubMed
    1. Aroniadis O. C., Brandt L. J., Oneto C., Feuerstadt P., Sherman A., Wolkoff A. W., et al. . (2019). Faecal Microbiota Transplantation for Diarrhoea-Predominant Irritable Bowel Syndrome: A Double-Blind, Randomised, Placebo-Controlled Trial. Lancet Gastroenterol. Hepatol. 4 (9), 675–685. doi: 10.1016/S2468-1253(19)30198-0 - DOI - PubMed
    1. Bosman M., Elsenbruch S., Corsetti M., Tack J., Simren M., Winkens B., et al. . (2021). The Placebo Response Rate in Pharmacological Trials in Patients With Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Lancet Gastroenterol. Hepatol. 6 (6), 459–473. doi: 10.1016/S2468-1253(21)00023-6 - DOI - PubMed
    1. Camilleri M. (2021). Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA 325 (9), 865–877. doi: 10.1001/jama.2020.22532 - DOI - PubMed
    1. Carroll I. M., Ringel-Kulka T., Siddle J. P., Ringel Y. (2012). Alterations in Composition and Diversity of the Intestinal Microbiota in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Neurogastroenterol. Motil. 24 (6), 521–530, e248. doi: 10.1111/j.1365-2982.2012.01891.x - DOI - PMC - PubMed

Publication types